Abstract: A display device includes a substrate. The substrate includes a display area and a non-display area, and the display area includes an emission area and a non-emission area. A display element layer includes a light emitting element on the emission area of the substrate. A bank is on the display element layer and overlaps the non-display area and the non-emission area of the substrate in a plan view. A color conversion layer is on the display element layer, overlaps the emission area in the plan view, and is to convert a color of light emitted from the light emitting element. An organic insulating layer is on the color conversion layer and the bank. A maximum thickness of the bank is about 4 ?m to about 20 ?m. An average inclination angle of a first side surface of the bank adjacent to an edge of the substrate in the non-display area based on an upper surface of the substrate is less than or equal to about 45 degrees.

Abstract: A display device includes a light emitting element disposed on a substrate. A color conversion layer is disposed on the light emitting element, the color conversion layer including color conversion particles that convert light of a first color emitted from the light emitting element into light of a second color. An insulating layer is disposed on the color conversion layer. The insulating layer includes a first inorganic layer overlapping the color conversion layer, a second inorganic layer disposed on the first inorganic layer, and a third inorganic layer disposed on the second inorganic layer. A second porosity of the second inorganic layer is greater than a first porosity of the first inorganic layer. A second porosity of the second inorganic layer is greater than a third porosity of the third inorganic layer.

Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

Abstract: A pixel is disclosed that includes: a substrate; a pixel circuit disposed on the substrate and including at least one transistor and at least one capacitor; a first contact metal disposed on the substrate and to which a constant voltage is applied; an inorganic layer covering the first contact metal; a first pixel electrode disposed on the inorganic layer and electrically connected to the pixel circuit; a pixel defining film disposed on the first pixel electrode; a second contact metal disposed on the pixel defining film and electrically connected to the first contact metal; a separator disposed on the second contact metal; an organic light emitting portion disposed on the first pixel electrode; and a second pixel electrode disposed on the organic light emitting portion and connected to the second contact metal.

Abstract: Proposed is a method for providing an emoticon input interface by a user terminal. The method may include displaying a first input interface for inputting an emoticon to be posted on a profile page of a user. The method may also include receiving a selection interaction of selecting a first emoticon to be posted on the profile page of the user via the first input interface, and displaying the selected first emoticon on the profile page of the user. The first input interface may include user custom information associated with emoticon historical information of the user. The user custom information may be identical to at least a part of user custom information for a second input interface for inputting an emoticon to be displayed in a chat message.

Abstract: A display device includes a light emitting element disposed on a substrate. A color conversion layer is disposed on the light emitting element, the color conversion layer including color conversion particles that convert light of a first color emitted from the light emitting element into light of a second color. An insulating layer is disposed on the color conversion layer. The insulating layer includes a first inorganic layer overlapping the color conversion layer, a second inorganic layer disposed on the first inorganic layer, and a third inorganic layer disposed on the second inorganic layer. A second porosity of the second inorganic layer is greater than a first porosity of the first inorganic layer. A second porosity of the second inorganic layer is greater than a third porosity of the third inorganic layer.

Abstract: A display device includes a display area including a first light-emitting area and a second light-emitting area; a peripheral area adjacent to the display area; pixels which emit incident light; an encapsulation layer covering the pixels; a first color-converting pattern corresponding to the first light-emitting area and having a refractivity; a transmission pattern corresponding to the second light-emitting area and through which the incident light is transmitted; a low refractivity layer is in the display area and facing the encapsulation layer with each of the first color-converting pattern and the transmission pattern therebetween, the low refractivity layer including: a resin and a hollow particle which define a refractivity lower than the refractivity of the first color-converting pattern; and a first dam structure in the peripheral area and spaced apart from the display area, the first dam structure and the transmission pattern being portions of a same material layer.

Abstract: A display device includes a bank including an opening defining a plurality of pixels; a plurality of light emitting elements disposed in the plurality of pixels; a color conversion layer disposed on the plurality of light emitting elements in the opening; and a low refractive layer disposed on the color conversion layer in the opening.

Abstract: The present invention relates to an animal model in which social dominance is absent, and a pharmaceutical composition for preventing or treating diseases associated with the absence or reduction of social dominance. In an animal model, according to the present invention, social dominance is absent through inhibiting of the expression or activity of a CREB-regulated transcription coactivator 3 (CRTC3) gene or protein, and the animal model can be used as a model for diseases associated with the absence or reduction of social dominance. In addition, the present invention enables the prevention, alleviation or treatment of diseases associated with the absence or reduction of social dominance by using a composition containing agonists for brain epidermal growth factor (EGF) receptors.

Abstract: The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

Abstract: The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

Abstract: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

Abstract: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.